French unions urge government to takeover ArcelorMittal sites
The company announced plans last month to cut 600 jobs across the seven sites
Trade unionists in front of Arcelor Mittal headquarters in Saint Denis in France on May 13, 2025. (Photo by DANIEL PERRON/Hans Lucas/AFP via Getty Images)
Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
UNIONS in France fighting to save 600 jobs at ArcelorMittal operations in the country called for the government to take control of them, along the lines of what has happened to British Steel.
CGT union chief Sophie Binet promised hundreds of workers demonstrating outside ArcelorMittal's offices of its French subsidiary in France that she would press the issue with president Emmanuel Macron.
"I will deliver to him the CGT proposals to nationalise" the group's French operations, she told the protesting workers.
ArcelorMittal announced plans last month to cut 600 jobs across the seven sites it has in France, from a total workforce in the country of around 7,100 people. It is in the process of negotiating the job reductions with unions.
The group -- the second-biggest steelmaker in the world, formed from a merger of India's Mittal Steel with European company Arcelor -- has warned of industry "uncertainty" after the US imposed 25-per cent tariffs on steel and aluminium imports.
Yet the group in April posted a quarterly group net profit of $805 million (£633m). To shave costs, it is shifting some support jobs from Europe to India, and last year it suspended a $2 billion (£1.57bn) decarbonisation investment in France.
French unions believe Macron's government can follow the lead of its British counterpart, which last month passed a law allowing it to take control of ailing British Steel.
Italy last year also ousted ArcelorMittal as owner of its debt-ridden ex-Ilva plant, accusing the company of failing to prop up the operation after buying control in 2018.
"The Italians have done it, the British have done it... so why aren't we French able to also do it?" asked a regional CGT head, Gaetan Lecocq.
But a junior French minister for business, Veronique Louwagie, told parliament that "nationalisation is not a response in itself to the difficulties faced by the European steel industry".
She also said, however, that the government expected the company "to give what its mid-term strategy in France is".
A lawmaker with the hard-left France Unbowed party, Aurelie Trouve, has put forward a bill for the nationalisation of ArcelorMittal in France.
Trouve said the company "has clearly been organising the offshoring of production for years, and now we are faced with an emergency".
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.